Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 3/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
| ▸ | AKT2 | P31751 | 2/20 | 0.30 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193977 | 0.92 | TLR4 (0.43) | TLR4LPAR1SELP | |
| SCHEMBL4207505 | 0.89 | TLR4 (0.45) | TLR4TNFSLC2A1AKT1AKT2 | |
| SCHEMBL4199865 | 0.88 | TLR4 (0.45) | TLR4LPAR1 | |
| SCHEMBL4193974 | 0.85 | TLR4 (0.45) | TLR4TNFSLC2A1SELPMAPK1 | |
| SCHEMBL4192662 | 0.83 | TLR4 (0.44) | TLR4TNFLPAR1 | |
| SCHEMBL4204041 | 0.83 | TLR4 (0.43) | TLR4LPAR1 | |
| SCHEMBL4200285 | 0.81 | TLR4 (0.43) | TLR4LPAR1 | |
| SCHEMBL4199867 | 0.79 | TLR4 (0.49) | TLR4 | |
| SCHEMBL4193821 | 0.79 | TLR4 (0.43) | TLR4LPAR1 | |
| SCHEMBL4196596 | 0.78 | TLR4 (0.47) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | TLR4 294/4885TNF 2749/4885LPAR1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.